JAK inhibitors differentially modulate B cell activation, maturation and function: A comparative analysis of five JAK inhibitors in an in-vitro B cell differentiation model and in patients with rheumatoid arthritis

BACKGROUND: Janus kinase (JAK) inhibitors have been approved for the treatment of several immune-mediated diseases (IMIDs) including rheumatoid arthritis (RA) and psoriatic arthritis and are in clinical trials for numerous other IMIDs. However, detailed studies investigating the effects of different...

Descripción completa

Detalles Bibliográficos
Autores principales: Frede, Natalie, Lorenzetti, Raquel, Hüppe, Janika M, Janowska, Iga, Troilo, Arianna, Schleyer, Marei-Theresa, Venhoff, Ana C., Voll, Reinhard E., Thiel, Jens, Venhoff, Nils, Rizzi, Marta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908612/
https://www.ncbi.nlm.nih.gov/pubmed/36776828
http://dx.doi.org/10.3389/fimmu.2023.1087986

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908612/
https://www.ncbi.nlm.nih.gov/pubmed/36776828
http://dx.doi.org/10.3389/fimmu.2023.1087986

Ejemplares similares